Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinicsAmeeta E Singh
University of Alberta, Alberta, Canada
Sex Transm Dis 32:95-100. 2005
..The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics...
- Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics
Barbara Romanowski
University of Alberta, Edmonton, Alberta, Canada
Sex Transm Dis 30:33-8. 2003
..Hepatitis C virus (HCV) is a major global problem, transmitted primarily by percutaneous exposure to contaminated blood...
- Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study
Barbara Romanowski
University of Alberta, Edmonton, Alberta, Canada
Sex Transm Dis 30:226-31. 2003
..Valacyclovir is effective for suppressive and episodic treatment of recurrent genital herpes. Few data on patients' treatment strategy preferences are available...
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyBarbara Romanowski
University of Alberta, Edmonton, AB, Canada
Hum Vaccin 7:1374-86. 2011
..These results indicate that the HPV-16/18 vaccine on a 2D M0,6 schedule is immunogenic and generally well tolerated in girls 9-14 y and that the 2D schedule is likely adequate for younger females...
- Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines
Barbara Romanowski
University of Alberta, Edmonton, AB, Canada
Hum Vaccin 7:161-9. 2011
..Cross-protection against non-vaccine types appears stronger with the bivalent vaccine. However, both vaccines may provide sufficient immunogenicity to confer long-term protection. Ongoing monitoring is essential...
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 yearsB Romanowski
University of Alberta, 1000 8215 112 Street, Edmonton, AB, Canada, T6G 2C8
Lancet 374:1975-85. 2009
..Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years...
- Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada
Barbara Romanowski
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Sex Transm Dis 36:165-9. 2009
..To determine the seroprevalence of herpes simplex virus infection in a population of HIV-infected individuals in Canada...
- In search of optimal genital herpes management and standard of care (INSIGHTS): doctors' and patients' perceptions of genital herpes
B Romanowski
University of Alberta, Edmonton, Alberta, Canada
Sex Transm Infect 84:51-6. 2008
..To compare and contrast attitudes and behaviours of family doctors and patients with regard to genital herpes and its management...
- Serologic response to treatment of infectious syphilis
B Romanowski
STD Control, Alberta Health, Edmonton, Canada
Ann Intern Med 114:1005-9. 1991
..To evaluate the serologic response to treatment of patients with infectious syphilis...
- Interferon treatment of multiple pulmonary malignancies associated with papilloma virus
S Aaron
University of Alberta, Edmonton
Can Respir J 11:443-6. 2004
..Over the following seven years no new ones have appeared. The finding of papilloma virus in malignancies should prompt consideration of antiviral therapy...
- First year serologic response to treatment for syphilis: a model for prediction of seroreversion
M S Rose
Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta, Canada
Stat Med 16:2103-15. 1997
..We recommend development of an action line be developed based on these variables. Such a line would indicate the necessity for retreatment if the line plotted from the patient's first year response failed to fall below the action line...
- BVBlue test for diagnosis of bacterial vaginosis
Linda Myziuk
University of Alberta, Edmonton, Alberta, Canada
J Clin Microbiol 41:1925-8. 2003
..98 times more likely to have another episode of BV. BVBlue is a useful point-of-care diagnostic tool to provide a presumptive diagnosis of BV, especially in situations where microscopic capabilities are unavailable...
- Gonorrhea treatment guidelines in Canada: 2004 update
Janice Mann
Public Health Agency of Canada, Ottawa, Ont
CMAJ 171:1345-6. 2004
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
Gerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008
....
- Report of the 2003 pan-Canadian forum on cervical cancer prevention and control
Gavin Stuart
Faculty of Medicine, University of British Columbia, Vancouver BC
J Obstet Gynaecol Can 26:1004-28. 2004
..To develop evidence-based consensus recommendations on the delivery of cervical cancer screening, human papillomavirus (HPV) education, HPV testing, and the optimal tool for cervical cytology within the Canadian health system...
